BIO Bio-Rad Laboratories, Inc.

$369.32▲ +0.15% Healthcare Other
After hours $369.32▲ +0.08% Sep 11, 4:00 PM ET
Volume 344.8K Avg Volume (10D) 220.7K
Key Metrics & Fundamentals
Market Cap
$9.87B
P/E Ratio
44.9
Div Yield
–%
52W Range
236.73 - 396.23
% vs 50 MA
7.87%
% vs 200 MA
21.76%
RSI-14
51.8
MACD Histogram
-4.1700
Beta (1Y vs SPY)
0.77
Free Cash Flow
$66.70M
Gross Rev
$651.00M
Gross Profit
$345.80M
EBITDA
$136.80M
COGS
$305.20M
Operating Exp
$273.20M
Operating Income
$72.60M
EBIT
$72.60M
Pretax Income
$542.10M
Net Income
$371.40M
EPS (Diluted)
13.85
Price & Volume History
Loading chart…
Recent News
Transcriptome Sequencing Market - Global Forecast to 2035; Bulk RNA-Seq Maintains Its Technology Market Lead
GlobeNewswire · Sep 10, 2026 11:03 AM
ILMN Stock Keeps Climbing. Should You Climb On?
Trefis · Sep 8, 2026 7:37 PM
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
Zacks · Sep 4, 2026 3:30 PM
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
GlobeNewswire · Sep 4, 2026 9:48 AM
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
Zacks · Sep 3, 2026 3:30 PM
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
Business Wire · Aug 31, 2026 1:00 PM
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
Zacks · Aug 21, 2026 2:31 PM
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
Zacks · Aug 20, 2026 3:23 PM
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?
Insider Monkey · Aug 14, 2026 12:13 AM
Bio-Rad (BIO) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 12, 2026 12:00 AM
Financial Overview - Income Statement Quarterly

See BIO's money flow as a full page

Social Sentiment
Avg +0.12 · 57 posts
NewsPriceTargetOppenheimer raises Q32 Bio stock price target on trial data to $40
r/wallstreetbets · Jul 13, 2026
An Oppenheimer price target increase suggests a positive outlook on the stock's future performance.
positive +0.60
DiscussionRelay Therapeutics up AGAIN today
r/wallstreetbets · Jun 30, 2026
The context relates to the broader biotech industry represented by companies like BIO.
positive +0.60
Why it’s not too late to get in: The Asymmetric Case for Nebius ($NBIS)
r/stocks · Jan 24, 2026
The comments express significant concerns about BioPharmX's profitability and unsustainable growth, indicating a bearish sentiment.
negative -0.60
NewsDiscussionThe treatment for cancer vs shorters (IBRX) BUY BUY BUY
r/wallstreetbets · Jan 23, 2026
The post highlights Immunity Bio's positive clinical trial results, suggesting a positive outlook for the company.
positive +0.80
DiscussionTradeThe duality of small biotechs
r/wallstreetbets · Jan 2, 2026
The author expresses a negative outlook on BIO, anticipating 'they both go bust'.
negative -0.80
Page 1 of 12 (57 total)
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙